Waters Co. (NYSE:WAT - Free Report) - Investment analysts at Leerink Partnrs increased their Q3 2025 earnings per share (EPS) estimates for shares of Waters in a note issued to investors on Wednesday, February 12th. Leerink Partnrs analyst P. Souda now expects that the medical instruments supplier will earn $3.20 per share for the quarter, up from their prior forecast of $3.12. The consensus estimate for Waters' current full-year earnings is $11.79 per share. Leerink Partnrs also issued estimates for Waters' Q1 2026 earnings at $2.45 EPS, Q2 2026 earnings at $3.21 EPS, Q3 2026 earnings at $3.62 EPS and Q4 2026 earnings at $4.77 EPS.
Waters (NYSE:WAT - Get Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.02 by $0.08. Waters had a return on equity of 49.93% and a net margin of 21.43%.
A number of other equities analysts have also issued reports on the company. Sanford C. Bernstein raised Waters from a "market perform" rating to an "outperform" rating and set a $430.00 price target for the company in a research note on Friday, January 10th. Deutsche Bank Aktiengesellschaft increased their price target on Waters from $310.00 to $325.00 and gave the company a "hold" rating in a research note on Monday, November 4th. StockNews.com raised Waters from a "hold" rating to a "buy" rating in a research note on Monday. Scotiabank raised Waters from a "sector perform" rating to a "sector outperform" rating and increased their price target for the company from $430.00 to $450.00 in a research note on Thursday, February 13th. Finally, Stifel Nicolaus raised their price objective on Waters from $332.00 to $360.00 and gave the stock a "hold" rating in a research note on Monday, November 4th. Ten analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $390.40.
Read Our Latest Stock Report on Waters
Waters Price Performance
NYSE WAT traded up $7.00 on Friday, reaching $376.73. 590,243 shares of the stock traded hands, compared to its average volume of 460,108. The firm's fifty day simple moving average is $389.12 and its 200 day simple moving average is $365.09. The company has a quick ratio of 1.38, a current ratio of 2.02 and a debt-to-equity ratio of 1.14. The company has a market cap of $22.37 billion, a price-to-earnings ratio of 35.95, a P/E/G ratio of 7.37 and a beta of 1.01. Waters has a 12 month low of $279.24 and a 12 month high of $423.56.
Institutional Trading of Waters
A number of institutional investors have recently bought and sold shares of the company. Advisory Alpha LLC boosted its position in Waters by 2.6% during the fourth quarter. Advisory Alpha LLC now owns 1,065 shares of the medical instruments supplier's stock valued at $395,000 after purchasing an additional 27 shares during the last quarter. Summit Trail Advisors LLC boosted its position in Waters by 2.4% during the third quarter. Summit Trail Advisors LLC now owns 1,198 shares of the medical instruments supplier's stock valued at $431,000 after purchasing an additional 28 shares during the last quarter. Empowered Funds LLC boosted its position in Waters by 3.0% during the fourth quarter. Empowered Funds LLC now owns 966 shares of the medical instruments supplier's stock valued at $358,000 after purchasing an additional 28 shares during the last quarter. Deroy & Devereaux Private Investment Counsel Inc. lifted its position in shares of Waters by 0.3% in the fourth quarter. Deroy & Devereaux Private Investment Counsel Inc. now owns 9,610 shares of the medical instruments supplier's stock worth $3,565,000 after buying an additional 30 shares during the last quarter. Finally, OneDigital Investment Advisors LLC lifted its position in shares of Waters by 3.8% in the third quarter. OneDigital Investment Advisors LLC now owns 851 shares of the medical instruments supplier's stock worth $306,000 after buying an additional 31 shares during the last quarter. Institutional investors and hedge funds own 94.01% of the company's stock.
About Waters
(
Get Free Report)
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.
Read More
Before you consider Waters, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Waters wasn't on the list.
While Waters currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
